U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07943325) titled 'Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer' on Nov. 09.

Brief Summary: This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.

Study Start Date: Feb., 2027

Study Type: INTERVENTIONAL

Condition: Advanced NSCLC Metastatic NSCLC - Non-Small Cell Lung Cancer

Intervention: DRUG: Cisplatin

Dose per standard-of-care

DRUG: Carboplatin

Dose per standard-of-c...